Search

Displaying results 4121 - 4130 of 4588 in total
  1. Drug

    Brecanavir

    go.drugbank.com/drugs/DB04887
    Investigational

    Brecanavir (VX-385) an orally active aspartic protease inhibitor (PI), under investigation by Vertex and GlaxoSmithKline for the treatment of HIV.

  2. Drug

    Ibrigampar

    go.drugbank.com/drugs/DB05490
    Investigational

    AMG-131 (T131), an orally-administered therapy, is expected to lower blood glucose in type II diabetic patients by improving the body’s ability to respond to insulin.

  3. Drug

    MVC-COV1901

    go.drugbank.com/drugs/DB15854
    Investigational

    MVC-COV1901 is a vaccine candidate developed and commercialized by Medigen Vaccine Biologics Corporation. The vaccine candidate contains a perfusion form of the SARS-Cov2 recombinant spike protein.

  4. Drug

    SAR445136

    go.drugbank.com/drugs/DB17708
    Investigational

    It consists of autologous CD34+ hematopoietic stem precursor cells (HSPC) modified ex vivo by zinc finger nucleases (ZFN) that target the BCL11A gene erythroid-specific enhancer (ESE) to increase endogenous

  5. Drug

    Hydrocortisone acetate

    go.drugbank.com/drugs/DB14539
    ApprovedInvestigationalVet approved

  6. Drug

    Hydrocortisone valerate

    go.drugbank.com/drugs/DB14544
    ApprovedVet approved

  7. Drug

    Pyrazinamide

    go.drugbank.com/drugs/DB00339
    ApprovedInvestigational

    A pyrazine that is used therapeutically as an antitubercular agent.

  8. Drug

    Hydrocortisone cypionate

    go.drugbank.com/drugs/DB14541
    ApprovedVet approvedWithdrawn

  9. Drug

    ARX201

    go.drugbank.com/drugs/DB05082
    Investigational

    human growth hormone that has been modified using Ambrx’s patented ReCODE™ technology to achieve precise spatial positioning of the site of polyethylene glycol (PEG) attachment to human growth hormone, by

  10. Drug

    Carfilzomib

    go.drugbank.com/drugs/DB08889
    ApprovedInvestigational

    Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treat...